Revaprazan
Based on 2 publication(s) in Google Scholar
Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer.
For research use only. We do not sell to patients.
- CAS No.: 199463-33-7
- Formula: C22H23FN4
- Molecular Weight:362.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Revaprazan
More
Biological Activity
|
COX-2 |
Revaprazan (5-20 μM, 24 h) reduces H. pylori-stimulated COX-2 expression and activity in AGS cells[1].
Revaprazan (5-20 μM, 24 h) inhibits transcription activity of NF-κB in H. pylori-stimulated AGS cells[1].
Revaprazan (5-20 μM, 24 h) improves the retarded cell growth in H. pylori-stimulated AGS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H. pylori-stimulated AGS cells
-
Concentration:5 and 20 μM
-
Incubation Time:24 h
-
Result:Reduced COX-2 expression.
Inhibited transcription activity of NF-κB.
Inactivated ERK and Akt phosphorylation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 199463-33-7
-
Molecular Weight 362.44
-
Formula C22H23FN4
-
SMILES
CC1=C(C)C(N2C(C)C3=C(C=CC=C3)CC2)=NC(NC4=CC=C(F)C=C4)=N1
-
Synonyms
SB 641257
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pharmaceuticals (Basel)
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells. [Abstract]2022 Sep 25;15(10):1186. PMID: 36297298 -
BMC Microbiol
In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus. [Abstract]2025 Nov 5;25(1):715. PMID: 41194018
Purity & Documentation
References
[1]. Lee JS, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J Clin Biochem Nutr. 2012 Sep;51(2):77-83. [Content Brief]
[2]. Kim HK, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010 Oct;25(10):1618-25. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Revaprazan Related Classifications
HY-121851 Related Classifications
Powered by Bioz